<DOC>
	<DOCNO>NCT02786563</DOCNO>
	<brief_summary>Prospective , post-marketing , multi-center , open-label study explore initiation adalimumab could influence grey-scale ( GS ) power Doppler ( PD ) ultrasonographic ( US ) score use 36-joint plus 4-tendon scoring system , validate applicability different simplify US joint score system .</brief_summary>
	<brief_title>Changes Ultrasonographic Assessment Inflammation Upon Initiation Adalimumab Combination Therapy Chinese Rheumatoid Arthritis ( RA ) Patients With Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate severe RA despite treatment methotrexate ( MTX ) . Eligible use adalimumab accord local label without contraindication . Na√Øve adalimumab , participant prior exposure biologic diseasemodifying antirheumatic drug ( DMARDs ) experience least five halflives biologics treatment discontinuation . Participants investigator decide prescribe adalimumab per local label initiate adalimumab baseline . Other inflammatory condition may affect sign joint ultrasound ( eg , gouty arthritis , chronic rheumatic disease besides RA ) . Currently treat treated investigational drug chemical biologic nature within minimum 30 day baseline visit . Participants contraindication appropriate use adalimumab accord local label investigator ' judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ultrasonographic ( US )</keyword>
	<keyword>rheumatoid arthritis ( RA )</keyword>
	<keyword>C-reactive protein ( CRP )</keyword>
	<keyword>power doppler ( PD )</keyword>
	<keyword>disease activity scale ( DAS )</keyword>
</DOC>